Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples